Vimpat
Product Images NDC 70166-617

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Vimpat (NDC 70166-617). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lohxa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display 20 Units (Lacosamide 11)

Principal Display 20 Units (Lacosamide 11)
NDC 70166-617-10 RXONLY VIMPAT (lacosamide) is an oral solution to be used only for oral intake. Each unit of VIMPAT comprises 20 vials containing 10 mL of the solution. The medicine's oral solution contains 10mg of Lacosamide per 1 mL dosage form. A standard dose of 200mg (equal to 20 mL) of the oral solution contains 0.32mg phenylalanine. The product should be stored at a controlled temperature between 20-25°C. The specifications for administering the dosage are available in the insert. The product is suitable for institutional use only and has been repackaged by LOHXA.*
FDA Label Image

Chemical Structure (Vimpat 01)

FDA Label Image

Figure 1 (Vimpat 02)

Figure 1 (Vimpat 02)
The text appears to be a description of a figure showing the reduction in seizure frequency (in median percentage) for different doses in two studies (Study 2 and Study 4). The figure displays a chart with percentages on the Y-axis and different dose levels on the X-axis. However, the chart itself is not present in the text, so a description of the visual representation is not available.*
FDA Label Image

Figure 2 (Vimpat 03)

Figure 2 (Vimpat 03)
This is a description of Figure 2, which shows the proportion of patients who responded to treatment with VIMPAT at different dosages, compared to placebo. The responder rate- patients who showed improvement or no change in seizure frequency- was higher in the VIMPAT groups than the placebo group. The figure displays data from several studies, including N values for each treatment group at different dosages.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.